ASP Isotopes signs $1M/yr Gd-160 supply deal with Isotopia for Tb-161 cancer therapy

ASP Isotopes Inc.

Four-year supply agreement for enriched Gadolinium-160 starting 2026; minimum $1M per annum.
Gd-160 is precursor for Terbium-161, used in targeted radiotherapies for prostate cancer and neuroendocrine tumours.
Isotopia will use ASP Isotopes' Quantum Enrichment technology; plant to also produce Ni-64, Zn-68, Yb-176, Li-6/7.
ASP Isotopes expects additional Gd-160 orders during 2025 and is in discussions with other customers.
Company also announced an investor access event in South Africa from June 16-18, 2025, with facility tours.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.